| 摘要: |
| 目的 基于网络药理学探究槐杞黄颗粒治疗溃疡性结肠炎的分子机制并通过体内实验验证,为临床用药提供理论指导。方法 通过TCSMP和BATMAN-TCM获取槐杞黄颗粒活性成分及靶点;溃疡性结肠炎相关的靶基因从GeneCards、DisGeNet和OMIM数据库中提取;Venn图预测治疗溃疡性结肠炎的潜在靶点;利用String平台和Cytoscape 软件构建蛋白质相互作用网络(PPI);在Metascape平台进行基因本体论(Go)和京都基因和基因组百科全书(KEGG)路径富集分析;Cytoscape构建“中药-成分-靶点-疾病网络”可视化结果。通过体内实验测定槐杞黄颗粒对溃疡性结肠炎小鼠体质量、结肠长度,疾病活动指数(DAI)和结肠黏膜损伤指数(CMDI)及病理形态;酶联免疫吸附测定法(ELISA)检测小鼠血清IL-36α、IL-36γ、IL-1β、TNF-α、IL-6水平;Western blot法检测结肠组织phospho-p38 MAPK的表达。结果 通过网络药理学获得槐杞黄颗粒的52种活性成分,261个潜在治疗靶基因,关键靶点有IL-1β、TNF-α、IL-6和MAPKs等。KEGG富集分析得到癌症信号通路,MAPK信号通路等。体内实验发现与模型组相比,槐杞黄颗粒治疗组体质量和结肠长度显著增加,DAI和CDMI 评分显著下降,结肠病理情况显著缓解,血清IL-36α、IL-36γ、IL-1β、TNF-α、IL-6和结肠组织phospho-p38 MAPK的表达显著降低(P<0.05,P<0.01)。结论 槐杞黄颗粒可能通过IL-36/p38MAPK信号通路,缓解溃疡性结肠炎小鼠的肠道炎症。 |
| 关键词: 槐杞黄颗粒 溃疡性结肠炎 网络药理学 白细胞介素-36 p38 MAPK |
| DOI:10.13506/j.cnki.jpr.2025.05.005 |
| 基金项目:济南市卫生健康委员会科技计划项目(No.2022-2-133) |
|
Publication Date:May 25, 2025
|
|
| Network pharmacology analysis and experimental validation of the mechanism of action of Huaiqihuang Granules in the treatment of ulcerative colitis |
| LIN Jianjuan,FAN Jinjun,XU Juan,QI Ran,QU Wenjing |
| (The Second Children & Women’s Healthcare of Jinan City, Jinan 271199, Chin) |
| Abstract: |
| Objective The aim of this study was to explore the molecular mechanisms of Huaiqihuang Granules in the treatment of ulcerative colitis based on network pharmacology and validate them through in vivo experiments, providing theoretical guidance for clinical medication. Methods Active ingredients and targets of Huaiqihuang Granules were obtained from TCSMP and BATMAN-TCM; target genes related to ulcerative colitis were extracted from GeneCards, DisGeNet, and OMIM databases; Venn diagram was used to predict potential targets for the treatment of ulcerative colitis; protein-protein interaction network (PPI) was constructed using the String platform and Cytoscape software; gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed on the Metascape platform; a "Chinese medicine-ingredients-targets-disease network" was visualized using Cytoscape. In vivo experiments were conducted to evaluate the effects of Huaiqihuang Granules on body weight, colon length, disease activity index (DAI), colonic mucosal damage index (CMDI), and pathological morphology in mice with ulcerative colitis; enzyme-linked immunosorbent assay (ELISA) was used to measure serum levels of IL-36α, IL-36γ, IL-1β, TNF-α, and IL-6 in mice; Western blot analysis was performed to detect the expression of phospho-p38 MAPK in colonic tissues. Results Network pharmacology identified 52 active ingredients of Huaiqihuang Granules, 261 potential therapeutic target genes, with key targets including IL-1β, TNF-α, IL-6, and MAPKs. KEGG enrichment analysis revealed cancer signaling pathways, MAPK signaling pathways, etc. In vivo experiments showed that compared to the model group, the Huaiqihuang Granules treatment group had significantly increased body weight and colon length, decreased DAI and CMDI scores, alleviated colonic pathology, and significantly reduced the expression of serum IL-36α, IL-36γ, IL-1β, TNF-α, IL-6, and colonic tissue phospho-p38 MAPK (P<0.05, P<0.01). Conclusion Huaiqihuang Granules may alleviate intestinal inflammation in mice with ulcerative colitis through the IL-36/p38 MAPK signaling pathway. |
| Key words: Huaiqihuang Granules Ulcerative colitis Network pharmacology IL-36 p38 MAPK |